8-K: Tempest Therapeutics Acquires CAR T-Cell Assets, Appoints New CEO

Tempest Therapeutics announced the acquisition of four CAR T-cell therapy programs from Erigen LLC and Factor Bioscience Inc., alongside significant leadership changes and a planned capital raise.

Summary

• Tempest Therapeutics, Inc. (the Company) acquired assets primarily related to four CAR T-cell therapy programs (ERI-2003, ERI-2206, ERI-3003, ERI-3206) from Erigen LLC and Factor Bioscience Inc. (Sellers).
• The aggregate consideration for the acquisition is 8,268,495 shares of Tempest Common Stock, issued to Erigen.
• Post-closing, pre-Closing equityholders of Tempest will own approximately 35.0% of the Company, while Erigen's equityholders (Matt Angel, Ph.D. and Lotus Capital (BVI) Limited) are expected to own approximately 38.0% and 27.0%, respectively, on a fully diluted basis.
• Matt Angel, Ph.D., will be appointed as Tempest's President and Chief Executive Officer and a board member, replacing Stephen Brady, who will become Chairman of the board.
• Nicholas Maestas will continue as Chief Financial Officer and Head of Strategy.
• Geoff Nichol is expected to resign from the board of directors.
• The transaction is subject to stockholder approval, the appointment of Dr. Angel, and a pre-closing equity financing of at least $5.0 million.
• The Company plans to continue advancing amezalpat and TPST-1495, and will begin development of the acquired CAR T-cell programs (renamed TPST-2003, TPST-2206, TPST-3003, TPST-3206).
• A lock-up agreement restricts Erigen from transferring 50% of its shares for 180 days post-closing.
• The parties intend for the transaction to be treated as a tax-free reorganization under Section 368(a)(1)(C) of the Code.

Sentiment

Score: 7

Explanation: The filing outlines a significant strategic shift and pipeline expansion into CAR T-cell therapy, led by a new CEO with relevant expertise. This diversification and potential for high-value assets are positive. However, the substantial dilution for existing shareholders and the early-stage nature of the acquired assets mean that significant future capital raises and successful clinical development are required. The transaction is also subject to shareholder approval and financing. Given the high potential but also high risk and uncertainty, the sentiment is moderately positive.

Positives

• Expansion of pipeline with four new CAR T-cell therapy programs (ERI-2003, ERI-2206, ERI-3003, ERI-3206), diversifying the Company's therapeutic focus.
• Appointment of Matt Angel, Ph.D., an experienced co-founder and CEO of Factor Bioscience Inc., as the new CEO and President, bringing expertise in cell therapy.
• Continued advancement of existing programs amezalpat (first-line liver cancer) and TPST-1495 (Familial Adenomatous Polyposis, with National Cancer Institute funding for Phase 2).
• Pre-Closing Financing of at least $5.0 million is a condition for closing, providing immediate capital.
• The transaction is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes.

Negatives

• Significant dilution for existing shareholders, who will own approximately 35.0% of the Company post-closing.
• Reliance on future equity financing to advance pivotal development of amezalpat and other programs.
• Potential termination fee of $300,000 payable to Sellers under specified circumstances.
• The closing of the transaction is subject to several conditions, including stockholder approval and successful Pre-Closing Financing, introducing uncertainty.
• The acquired CAR T-cell programs are in early stages (preclinical to Phase 1b/2a in China), requiring substantial future development and funding.

Risks

• Risks and uncertainties related to the satisfaction of customary closing conditions for the Contemplated Transactions.
• Risk that the Company's stockholders may not approve the Contemplated Transactions.
• Risks that the Contemplated Transactions disrupt the current plans or operations of the Company.
• Risk that the Company is unable to obtain adequate financing to fund its operations on a timely basis or at all.
• Competitive responses to the Contemplated Transactions.
• Unexpected costs, charges or expenses resulting from the Contemplated Transactions.
• Potential adverse reactions or changes to relationships with commercial or other business partners resulting from the announcement or completion of the Contemplated Transactions.
• Requirement for additional capital to continue to advance the Company's product candidates, which may not be available on favorable terms or at all.
• The Company's ability to attract, hire, and retain skilled executive officers and employees.
• The Company's ability to protect its intellectual property and proprietary technologies.
• The Company's ability to achieve the benefits expected from the Contemplated Transactions, as well as delays, challenges and expenses associated with integrating the Assets.
• Risks related to the Company's plans to research, develop and commercialize its current and future product candidates, including the Assets.
• Risks concerning the clinical utility, potential benefits and market acceptance of the Company's product candidates.
• Impact of overall conditions in the biotech industry and general economy, including policy and regulatory changes.
• Risk that the Company may be adversely affected by other economic, business, or competitive factors.
• Geopolitical events, and regulatory, economic and other risks associated therewith.
• Continued uncertainty resulting from broader macroeconomic conditions.

Future Outlook

The Company intends to continue advancing its existing programs, amezalpat and TPST-1495, and will initiate preclinical and clinical development for the newly acquired CAR T-cell therapy programs (TPST-2003, TPST-2206, TPST-3003, TPST-3206). Future business development discussions or additional financing are planned to advance amezalpat's pivotal development in first-line liver cancer. A Phase 2 study for TPST-1495, funded by the National Cancer Institute, is expected to start in late 2026 or early 2027.

Management Comments

• The Company expects the Closing to occur in early 2026.
• The Company plans to pursue preclinical comparability activities to the study underway in China, pre-IND brief filings and then ultimately an IND submission to begin clinical development of TPST-2003 in the United States.
• With respect to the balance of the new programs, TPST-2206 is a preclinical-stage asset to which the Company plans to pursue preclinical activities, and based on such activities, may pursue future clinical development.
• Both TPST-3003 and TPST-3206 are discovery-stage assets to which the Company will pursue preclinical activities, and based on such activities, may pursue future clinical development.

Industry Context

This acquisition signifies Tempest Therapeutics' strategic pivot or expansion into the rapidly evolving CAR T-cell therapy space, a high-growth area in oncology and potentially autoimmune diseases. The move diversifies its pipeline beyond its current small molecule programs (amezalpat, TPST-1495) and positions it to compete with other biotech firms developing cell therapies. The appointment of a new CEO with a strong background in cell therapy (Factor Bioscience Inc.) further underscores this strategic direction. The reliance on future financing is common in early-stage biotech, especially for capital-intensive cell therapy development.

Comparison to Industry Standards

• The acquisition of preclinical and early-stage clinical assets is a common strategy for biotech companies seeking to expand their pipeline and enter new therapeutic modalities like CAR T-cell therapy.
• The significant dilution for existing shareholders (down to 35%) and the substantial ownership by the selling entity's equityholders (65%) is indicative of a reverse merger or a significant asset-for-equity transaction, which can be more dilutive than traditional financing rounds.
• The requirement for a $5.0 million pre-closing financing is a relatively modest amount for advancing multiple cell therapy programs, suggesting that substantial additional capital raises will be necessary in the future, consistent with industry norms for such capital-intensive development.
• The lock-up agreement for the selling entity's shares is standard practice to prevent immediate market dumping post-transaction.

Management Changes

Corporate Governance

Related Party Transactions

• The acquisition is from Erigen LLC and Factor Bioscience Inc., with Matt Angel, Ph.D. (Co-Founder, President, CEO, and Chairman of Factor Bioscience Inc.) becoming the new CEO of Tempest and a significant equityholder.
• Lotus Capital (BVI) Limited, an equityholder of Erigen, is expected to own 27.0% of Tempest post-closing.
• Erigen will amend and assign a master services agreement with Factor to Tempest, under which Factor will perform certain services for a period following the Closing.
• Factor has executed a commitment letter to provide funding to Purchaser until the earlier of the 18-month anniversary of the Closing Date or Purchaser raising aggregate gross proceeds of at least $20,000,000 (inclusive of any amounts raised in the Pre-Closing Financing).

Stakeholder Impact

• Shareholders: Significant dilution (existing shareholders to own ~35%), but potential for pipeline expansion and strategic growth. Warrants issued to existing shareholders provide some benefit. Required to vote on the transaction.
• Management/Employees: Major leadership changes with a new CEO and Chairman. Nicholas Maestas rehired full-time. Potential for new strategic direction and focus.
• Sellers (Erigen/Factor): Receive substantial equity in Tempest (65% combined ownership for Erigen's equityholders), indicating a strategic partnership and belief in the combined entity's future.
• Customers/Patients: Potential for new therapeutic options in CAR T-cell therapy for various diseases, alongside continued development of existing programs.

Next Steps

• Seek approval of the Contemplated Transactions by stockholders at a meeting.
• Consummate the Pre-Closing Financing of at least $5.0 million.
• Appoint Matt Angel, Ph.D. as President and Chief Executive Officer and a Class I director.
• Stephen Brady to assume the position of Chairman of the board.
• Geoff Nichol to resign from the board of directors.
• Issue warrants to existing stockholders.
• Closing of the Contemplated Transactions, expected in early 2026.
• Advance pivotal development of amezalpat in first-line liver cancer (HCC) through business development or additional financing.
• Support a Phase 2 study of TPST-1495 in Familial Adenomatous Polyposis, expected to start in late 2026 or early 2027.
• Pursue preclinical comparability activities, pre-IND filings, and IND submission for TPST-2003 in the United States.
• Pursue preclinical activities for TPST-2206, TPST-3003, and TPST-3206, potentially leading to future clinical development.
• Erigen to effect its liquidation and distribute Closing Consideration to equityholders within 10 business days of Closing.
• Purchaser to file a registration statement on Form S-1 for the resale of Registrable Securities within 30 days of Closing.

Key Dates

Recommendation

The acquisition of four CAR T-cell therapy programs and the appointment of a new CEO with relevant expertise represent a significant strategic pivot with potential for long-term growth in a high-value therapeutic area. This could be transformative for Tempest. However, the substantial dilution for existing shareholders and the early-stage nature of the acquired assets mean that significant future capital raises and successful clinical development are required. The transaction is also subject to shareholder approval and financing. Given the high potential but also high risk and uncertainty, a 'hold' recommendation is appropriate for investors to observe the integration, initial development progress, and successful execution of future financing rounds before making further investment decisions.

Keywords

Tempest Therapeutics, Erigen LLC, Factor Bioscience Inc., Asset Purchase Agreement, CAR T-cell therapy, ERI-2003, ERI-2206, ERI-3003, ERI-3206, TPST-2003, TPST-2206, TPST-3003, TPST-3206, Matt Angel, Stephen Brady, Nicholas Maestas, corporate governance, pipeline expansion, preclinical, clinical trials, oncology, autoimmune, liver cancer, Familial Adenomatous Polyposis, amezalpat, TPST-1495, equity financing, Nasdaq, SEC filing, biotechnology, pharmaceutical, M&A